Bartonella

Causes and drivers

Bartonella illness can involve animal, flea, lice, and possible tick exposure plus vascular, neurologic, immune, and biofilm/persister behavior.

The uploaded Bartonella and Mycoplasma materials emphasize endothelial cells, red blood cells, cytokine cascades, immune status, and co-infection synergy. Horowitz's 2025 Bartonella Substack series adds DDDCT, HDDCT, and pulsed antibiotic discussions for resistant Bartonella in Lyme/MSIDS patients.

Exposure sources

Bartonella henselae, B. quintana, B. vinsonii, and related organisms are associated with cats, fleas, body lice, animal exposure, and other biting arthropods; tick transmission remains debated but is evaluated by some Lyme-literate clinicians.

Symptom pattern

Bartonella discussions often start with foot-sole pain, shin pain, electric or burning nerve pain, swollen nodes, eye irritation, headaches, insomnia, agitation, sudden mood shifts, POTS-like symptoms, vascular symptoms, or streak-like skin changes.

Specialty workup

Clinicians may combine symptom pattern, CBC/CMP, inflammatory markers, VEGF context, serology, PCR, FISH, enrichment culture, eye evaluation, neuropsychiatric safety review, and co-infection testing.

Clinician-supervised treatment protocols

Two established pathways for persistent Bartonella: Horowitz HDDCT 6-day pulses and Mozayeni rifabutin+clarithromycin.

Bartonella is an intracellular, biofilm-forming pathogen that requires combination therapy for deep penetration. Two major clinical frameworks have emerged: Dr. Horowitz's dapsone-based approaches (same DDDCT/HDDCT framework as Lyme, with 6-day pulse duration for Bartonella) and the Mozayeni-informed rifabutin+clarithromycin protocol targeting Bartonella's endothelial and erythrocytic niches.

Horowitz advanced Bartonella protocol

HDDCT 6-Day Pulse — high-dose dapsone combination for persistent Bartonellosis

When Bartonella remains active after DDDCT foundational treatment, Horowitz advances to HDDCT with a 6–7 day pulse duration (aligned with the longer pulse arm studied in the 2023 paper, which found superior outcomes vs. 4-day pulses when Bartonella is present). The 6–7 day pulse delivers sustained high-concentration antimicrobial pressure against endothelial and erythrocytic Bartonella persisters.

HDDCT 6-day pulse core antimicrobial protocol for Bartonella

Medication	Pulse dose (6 days)	Mechanism against Bartonella	Schedule
Dapsone (high dose)	200 mg twice daily (400 mg/day)	Penetrates endothelial cells; biofilm/persister activity; folate pathway inhibition; anti-inflammatory	6 days on, 8–14 days off
Doxycycline	100 mg twice daily (200 mg/day)	Intracellular penetration; inhibits Bartonella protein synthesis; anti-inflammatory; biofilm suppression	Daily (continuous)
Rifampin	300 mg twice daily (600 mg/day)	RNA polymerase inhibition; strong intracellular activity; penetrates endothelial niche and biofilms	Daily (continuous)
Rifabutin (alternative)	150–300 mg twice daily (300–600 mg/day)	Potent anti-Bartonella rifamycin; fewer drug interactions than rifampin; preferred by some LLMDs for Bartonella specifically	Daily (continuous)
Methylene blue (adjunct)	50–100 mg twice daily (during pulse days)	Persister agent; mitochondrial support; anti-inflammatory; additive Bartonella activity	6 days on (during pulse only)

How the 6–7 day Bartonella pulse relates to the published study:

Extended pulse duration (6 vs. 4 days): Bartonella's doubling time is slower and its intracellular niche (endothelial cells, erythrocytes) makes it harder to reach. The extra 2 days of high-dose exposure improve penetration into sequestered bacterial populations.
Pulse frequency: Repeated every 3–4 weeks, with pre-pulse labs required before each cycle to confirm methemoglobin clearance and hematologic stability.
Total cycles: Typically 6–12 monthly pulse cycles, depending on neuropsychiatric symptom resolution, pain reduction, and functional improvement.
Rifabutin preference: In the Bartonella-specific protocol, many LLMDs prefer rifabutin over rifampin for its more favorable interaction profile (less CYP3A4 induction) and potent intracellular activity against Bartonella species.
Methylene blue: More commonly added for Bartonella-dominant cases than for Lyme-dominant cases, as methylene blue has independent anti-Bartonella properties.

* HDDCT 6-day pulses are among the most intensive Bartonella protocols. Neuropsychiatric flares are common during treatment as Bartonella die-off releases inflammatory cytokines. Requires close psychiatric safety monitoring, especially in patients with baseline anxiety, agitation, or mood instability. *

Mozayeni-informed first-line Bartonella protocol

Rifabutin + Clarithromycin — the Mozayeni intracellular Bartonella combination

Dr. Robert Mozayeni, former NIH Chief of Rheumatology and founder of the Bartonella Institute, has advanced a targeted intracellular protocol for Bartonella. The core principle: Bartonella resides primarily in endothelial cells and erythrocytes, so treatment must combine an intracellular-penetrating rifamycin with a macrolide that achieves high tissue concentrations. This protocol is commonly used as first-line Bartonella therapy and can also be layered with or used between dapsone pulses.

Mozayeni core Bartonella protocol

Medication	Typical dose	Mechanism against Bartonella	Duration
Rifabutin	150 mg twice daily (300 mg/day) or 300 mg once daily	Potent intracellular rifamycin; inhibits bacterial RNA polymerase; achieves high endothelial and tissue concentrations; less CYP3A4 induction than rifampin	3–6+ months (response-guided)
Clarithromycin	500 mg twice daily (1000 mg/day)	Macrolide-class; inhibits protein synthesis (50S ribosomal subunit); high intracellular accumulation; penetrates endothelial cells and macrophages; synergistic with rifabutin	3–6+ months (response-guided)
Doxycycline (optional third agent)	100 mg twice daily (200 mg/day)	Tetracycline-class; broad intracellular coverage; anti-inflammatory; additional anti-Bartonella activity; covers Lyme if co-infected	3–6+ months (if added)
Minocycline (alternative to doxycycline)	100 mg twice daily (200 mg/day)	More lipophilic than doxycycline; better CNS penetration; useful for neuropsychiatric Bartonella presentations	3–6+ months (if substituted)

Rationale for the rifabutin+clarithromycin combination:

Dual intracellular penetration: Rifabutin and clarithromycin both achieve high intracellular concentrations in endothelial cells — Bartonella's primary niche. The combination targets the pathogen where it lives, not just in the bloodstream.
Synergistic activity: The rifamycin+macrolide combination has demonstrated synergistic killing against intracellular Bartonella species in published research. Rifabutin inhibits RNA synthesis; clarithromycin blocks protein synthesis; together they disrupt two essential bacterial processes simultaneously.
Rifabutin over rifampin: Rifabutin induces CYP3A4 less than rifampin, reducing drug-drug interactions. This is important because many Lyme/Bartonella patients are on multiple medications (psychiatric, hormonal, pain, sleep). Rifabutin also has a longer tissue half-life.
Clarithromycin over azithromycin: Clarithromycin achieves higher intracellular concentrations and has a more favorable spectrum against Bartonella species. Azithromycin is sometimes used when GI tolerance of clarithromycin is poor.

Mozayeni protocol safety monitoring

Parameter	Baseline	During treatment
CBC with diff	Required	Monthly; watch for leukopenia (rifabutin), anemia
CMP (liver, kidney)	Required	Monthly; rifabutin and clarithromycin are hepatically metabolized
ECG / QT interval	Required	Clarithromycin can prolong QT; check if adding other QT-prolonging drugs
Eye exam (uveitis risk)	Baseline recommended	Rifabutin can cause uveitis; monitor for eye pain, redness, vision changes
Drug interaction review	Required	Rifabutin is a CYP3A4 substrate and mild inducer; clarithromycin is a CYP3A4 inhibitor — together they affect levels of many drugs (statins, benzodiazepines, hormones, psychiatric medications, anticoagulants)
Pregnancy test	Required	Rifabutin and clarithromycin are Pregnancy Category C; doxycycline is Category D

Additional agents used in Mozayeni-informed protocols:

TMP-SMX (trimethoprim-sulfamethoxazole): 1 DS tablet twice daily. Some LLMDs add TMP-SMX as a third or fourth agent. It provides additional intracellular folate pathway inhibition and may have synergistic activity with rifamycins against Bartonella.
Pyrazinamide: Discussed in selected cases where Bartonella appears resistant to first-line combinations. Requires close liver monitoring. Limited published evidence but used clinically by some Bartonella specialists.
Ciprofloxacin or levofloxacin: Fluoroquinolones have intracellular activity and some anti-Bartonella effect, but carry FDA black-box warnings for tendon rupture, neuropathy, and psychiatric effects. Generally reserved for cases where other combinations have failed and benefits clearly outweigh risks.

* Mozayeni protocols require experienced clinicians. The rifabutin+clarithromycin combination has significant drug interaction potential. It requires baseline and ongoing lab monitoring, ECG review, and neuropsychiatric safety assessment. Not a self-directed protocol. *

Entry-level dapsone protocol

DDDCT for Bartonella — the foundational dapsone course

The Double Dose Dapsone Combination Therapy (DDDCT) protocol for Bartonella follows the same core structure as the Lyme DDDCT protocol, with the same medications and doses. It serves as the necessary foundation before HDDCT pulsing can be used safely.

DDDCT core protocol — applicable to Lyme + Bartonella co-infection

Medication	Dose	Duration
Dapsone	100 mg twice daily (200 mg/day)	8–12 weeks continuous
Doxycycline	100 mg twice daily (200 mg/day)	8–12 weeks continuous
Rifampin	300 mg twice daily (600 mg/day)	8–12 weeks continuous
Rifabutin (alternative)	150 mg twice daily (300 mg/day)	8–12 weeks continuous

When Bartonella is the dominant co-infection, clinicians often select rifabutin over rifampin in the DDDCT backbone for its stronger anti-Bartonella intracellular activity and more manageable drug interaction profile. The clinical goal of DDDCT for Bartonella patients is to reduce the bacterial load to a level where the body's immune system can regain partial control before advancing to pulse therapy.

After completing the DDDCT course, patients who have partially responded but still have active Bartonella symptoms are candidates for the HDDCT 6-day pulse protocol or the 2-week pulsing strategy described in the next tab.

* Same safety infrastructure as Lyme DDDCT applies. G6PD, CBC, CMP, methemoglobin, ECG, pregnancy test, sulfa allergy, and drug interaction review required before starting. *

Post-DDDCT/HDDCT maintenance

Two-week pulsing strategy — Horowitz Bartonella maintenance protocol

Dr. Horowitz's March 5, 2025 Substack article describes a two-week pulsing approach for patients who have completed DDDCT and/or HDDCT courses but still have residual Bartonella symptoms. This lower-intensity, longer-cycle pulsing strategy is designed for sustained Bartonella suppression over months while reducing cumulative toxicity and drug exposure.

Two-week Bartonella maintenance pulse protocol

Phase	Medications	Duration
On-pulse (2 weeks)	Dapsone 100–200 mg bid + Doxycycline 100 mg bid + Rifabutin 150–300 mg bid (or Rifampin 300 mg bid). Optional: methylene blue 50 mg bid, pyrazinamide, or TMP-SMX depending on clinician assessment.	14 consecutive days per cycle
Off-pulse (2 weeks)	Doxycycline and Rifabutin/Rifampin continue. Dapsone and adjuncts are paused. Herbal antimicrobial support (cryptolepis, houttuynia, sida acuta, Japanese knotweed) is often maintained or increased during off weeks.	14 consecutive days per cycle
Total treatment arc	Repeat 2-week on / 2-week off cycles for 3–9 months, with pre-pulse lab clearance required before each on-cycle. Duration determined by symptom resolution, functional recovery, and lab stability.	3–9+ months

The two-week pulse recognizes that Bartonella's intracellular and biofilm-sequestered populations require prolonged, repeated antimicrobial exposure — but that continuous high-dose dapsone is not necessary once the bacterial burden has been substantially reduced by DDDCT and HDDCT. The off-weeks allow hematologic recovery while companion antibiotics and herbal support maintain suppression.

Supportive herbal antimicrobials used during off-weeks

Herb	Target	Notes
Cryptolepis sanguinolenta	Borrelia, Bartonella, Babesia	Broad-spectrum antimicrobial; active against persister forms; one of the most potent herbal anti-Bartonella agents
Houttuynia cordata	Bartonella, Mycoplasma	Primary herbal anti-Bartonella agent; also antiviral; used as tincture or capsule
Sida acuta	Bartonella, Babesia	Anti-Bartonella and anti-Babesia; often combined with cryptolepis and houttuynia
Japanese knotweed	Borrelia, Bartonella, Mycoplasma	Broad-spectrum antimicrobial; anti-inflammatory; source of resveratrol; disrupts biofilms
Samento (Cat's claw TOA-free)	Bartonella, Borrelia	Immune-modulating antimicrobial; enhances NK cell and lymphocyte activity

* Pulsing protocols require ongoing monitoring. Labs must be checked before each pulse cycle. Dapsone, even at lower doses, still carries hematologic risk. Do not self-pulse without clinician supervision. *

Zhang TCM & Brownstein iodine support

Herbal and nutritional supportive therapies for Bartonella

LLMDs commonly integrate herbal protocols alongside prescription antimicrobials. Dr. Zhang's TCM approach targets intracellular Bartonella, while Brownstein's iodine protocol supports immune function and detoxification of toxic halides that compete with iodine at cellular receptors.

Zhang Protocol — TCM herbal formula for Bartonella

Herb / Formula	Target	Notes
HH (Houttuynia cordata)	Anti-Bartonella, anti-Mycoplasma	Zhang Clinic primary herb for Bartonella. Anti-inflammatory; crosses blood-brain barrier for neuropsychiatric Bartonella symptoms.
Allicin (garlic extract)	Anti-Bartonella, biofilm disruption	Stabilized allicin penetrates intracellular niches. Synergistic with rifamycins and macrolides for Bartonella.
Circulation P	Microcirculation, endothelial support	Critical for Bartonella which infects endothelial cells lining blood vessels. Improves tissue penetration of antimicrobials into vascular niches.
Artemisinin (Artemisia annua)	Anti-parasitic co-infection coverage	Added when Babesia co-infection is present alongside Bartonella. Pulsed to minimize neurotoxicity.

Brownstein Iodine Protocol — supportive therapy for Bartonella

Component	Dose	Bartonella-specific rationale
Iodine/Iodide	12.5–50 mg/day	Antibacterial; concentrates in endothelial tissue and blood cells where Bartonella resides. Supports immune-mediated clearance of intracellular infection.
Vitamin C	3,000–6,000 mg/day	Antioxidant protection against Bartonella-driven vascular inflammation and oxidative stress.
Selenium	200–400 mcg/day	Glutathione peroxidase cofactor; protects endothelial cells from oxidative damage during antimicrobial therapy.
Unrefined salt	1–1.5 tsp/day	Chloride displaces bromide from iodine receptors. Bromide competes with iodine and is elevated in chronic illness populations.
Magnesium	400–800 mg/day	Vascular smooth muscle relaxation; reduces neuropsychiatric irritability common in Bartonella.
ATP CoFactors (B2 + B3)	B2 100 mg + B3 500 mg bid	Mitochondrial energy support. Brownstein: use if plateauing on iodine alone.

* Herbal and nutritional protocols should be discussed with an LLMD. Iodine dosing should be guided by loading test results. Start low and titrate. *

Buhner Protocol — core herbal protocol for Bartonella

Stephen Harrod Buhner's Bartonella protocol from Healing Lyme Disease Coinfections. These herbs target Bartonella's endothelial and erythrocytic niches.

Herb	Category	Key actions against Bartonella
Sida acuta	Primary Bartonella antimicrobial	Buhner's #1 herb for Bartonella. Anti-inflammatory; crosses blood-brain barrier for neuropsychiatric symptoms. Often combined with Houttuynia and Cryptolepis. Active against persister forms.
Houttuynia cordata	Primary Bartonella antimicrobial	Strongly anti-Bartonella. Also active against Mycoplasma. Antiviral properties for co-infections. Used as tincture or capsule.
Japanese Knotweed (Polygonum cuspidatum)	Anti-inflammatory / antimicrobial	Core anti-inflammatory for cytokine mediation. Protects endothelial cells from Bartonella damage. Reduces systemic inflammation across vascular beds.
Isatis tinctoria (Woad)	Antimicrobial	Broad-spectrum antibacterial and antiviral. Traditional Chinese medicine for infections. Synergistic with other herbs in the protocol.
Alchornea cordifolia	Antimicrobial / anti-inflammatory	Active against Bartonella species. Also anti-Babesia. Protects endothelial integrity disrupted by Bartonella infection.
Hawthorn (Crataegus spp.)	Cardioprotective / circulatory	Protects heart and vascular tissue from Bartonella-mediated damage. Stabilizes collagen in blood vessel walls. Reduces palpitations and vascular inflammation.
EGCG (green tea extract)	Biofilm / anti-inflammatory	Disrupts Bartonella biofilm matrix. Potent anti-inflammatory. Protects endothelial cell junctions.

Detailed clinical picture

Bartonella can look vascular, neurologic, psychiatric, skin-deep, and systemic all at once.

The goal is not to force every symptom into Bartonella. It is to document patterns that justify a careful differential diagnosis, including Mycoplasma, Lyme, Babesia, mold/CIRS, MCAS, POTS, and non-infectious causes.

Bartonella-focused clues

Pain pattern: sole-of-foot pain, shin pain, rib pain, migrating bone pain, tendon pain, burning nerves, electric shocks, and pain that seems out of proportion to imaging.
Skin and vessels: streak-like marks, papules, angioma-like spots, stretch-mark-like lesions not explained by growth or weight change, easy flushing, and vascular inflammation clues.
Brain and nervous system: insomnia, agitation, sudden anxiety, irritability, intrusive thoughts, rage-like episodes, headaches, tremor, seizures, neuropathy, and POTS-like symptoms.
Eyes, glands, gut, urinary: eye pain or redness, light sensitivity, swollen lymph nodes, abdominal pain, nausea, bladder irritation, pelvic pain, and sore throat.

Mycoplasma and overlap factors

Respiratory history, chronic cough, sore throat, immune activation, joint pain, neuropathy, profound fatigue, and autoimmune-like symptoms can make Mycoplasma relevant.
Bartonella and Mycoplasma may be separate issues, immune stressors, or part of a larger Lyme-MSIDS pattern.
Bring prior pneumonia history, immune labs, inflammatory markers, medication reactions, psychiatric history, and any worsening after immune stress, mold exposure, surgery, childbirth, or severe viral illness.
Because Bartonella tick transmission remains debated in parts of medicine, clinicians weigh tick exposure, cat/flea exposure, symptoms, and test limitations together.

Bartonella/Mycoplasma appointment guide

Area	Details worth documenting	Clinician evaluation focus
Exposure	Tick bite, cat scratch or bite, flea exposure, lice exposure, animal rescue work, shelter work, travel, and household pet illness.	Species and vector fit, plus whether Mycoplasma belongs in the differential.
Testing	Prior Bartonella henselae or quintana serology, PCR, enrichment culture, blood smear comments, CBC, liver enzymes, inflammatory markers, and immune status.	Negative-result interpretation when symptoms and exposure remain strongly suggestive.
Neuropsychiatric safety	Sudden anxiety, depression, intrusive thoughts, rage-like episodes, insomnia, suicidality, seizure history, and medication sensitivity.	Psychiatric support, interaction review, and stop rules before antimicrobial escalation.
Sequencing	Mold/CIRS, MCAS, constipation, sleep deprivation, POTS, hormone issues, gut intolerance, and detoxification sensitivity.	Stabilization priorities that reduce unsafe flares during treatment.

Recommended Bartonella and Mycoplasma tests to discuss

Testing category	Horowitz / Mozayeni / Kinderlehrer focus	Common tests and labs to discuss
Bartonella serology	Mozayeni and Breitschwerdt emphasize species-aware interpretation because Bartonella is diverse and can be missed if only one species is checked.	Bartonella henselae, quintana, vinsonii, koehlerae, and other species by IFA/IgG/IgM where available; repeat or expanded testing when cat/flea/lice exposure, striae, neurologic symptoms, or vascular clues remain strong.
Direct Bartonella detection	Mozayeni-informed workups often combine antibody testing with direct methods because Bartonella can be intracellular, low-level, and intermittently present in blood.	Galaxy ePCR with BAPGM enrichment culture or triple-draw strategy, TLab or IGeneX Bartonella FISH, Bartonella PCR, tissue PCR/biopsy support when endocarditis, lymph node, ocular, or skin findings justify it.
End-organ evaluation	Horowitz and Kinderlehrer both stress that Bartonella can present as vascular, neurologic, psychiatric, eye, skin, or pain syndromes; testing may need to follow the organ system involved.	Eye exam for uveitis/retinitis/neuroretinitis symptoms, ECG or echocardiogram and blood cultures for endocarditis clues, neurologic evaluation for seizures or severe neuropathy, skin/vascular exam, POTS/autonomic testing when indicated.
Mycoplasma overlap	Kinderlehrer-style complex chronic Lyme care often screens Mycoplasma when respiratory history, autoimmune-like symptoms, neuropathy, joint pain, or profound fatigue overlap with Bartonella/Lyme.	Mycoplasma pneumoniae IgG/IgM and PCR when respiratory or systemic symptoms fit; MDL or specialty PCR for M. fermentans, M. hominis, M. penetrans, and broader Mycoplasma species when clinically relevant.
Co-infections and immune context	Horowitz's MSIDS model asks whether Lyme, Babesia, Mycoplasma, mold/CIRS, MCAS, immune suppression, or viral reactivation is keeping Bartonella symptoms active.	Lyme/Borrelia immunoblot or PCR when indicated, Babesia smear/PCR/FISH/IFA, Anaplasma/Ehrlichia/Rickettsia tests by geography, CBC/CMP, ESR/CRP, ferritin, vitamin D/B12/folate, thyroid, ANA/RF when autoimmune overlap is suspected.
Treatment safety monitoring	Mozayeni's rifabutin/macrolide approach and Horowitz's dapsone protocols both require baseline and follow-up safety labs.	CBC with differential, CMP/liver enzymes, bilirubin, ECG/QT review for macrolides and other QT drugs, pregnancy test when relevant, eye-symptom monitoring for rifabutin-associated uveitis, G6PD and methemoglobin if dapsone or methylene blue are used.

* Bartonella tests can be falsely negative. Use exposure history, symptom pattern, objective findings, and clinician judgment alongside lab results; do not self-prescribe based on a lab panel. *

Educational images

Bartonella biofilms, microscopy, and clinical skin patterns.

Biofilm and clinical-sign visuals are included for educational context. Confirm image-use permission before final public launch for any non-public-domain slide material.

Bartonella striae or stretch-mark-like abdominal skin findings from Horowitz Substack

Bartonella striae - characteristic stretch marks

Reddish or purplish streak-like marks are frequently discussed in Lyme-literate clinical resources as a possible Bartonella clue, especially when they are not explained by weight change or ordinary stretch marks. They are not diagnostic by themselves.

Source: Richard I. Horowitz, MD / Medical Detective educational material.

Cat scratch disease inoculation lesion

Cat scratch disease can begin with a small papule or lesion near the scratch or bite site, followed by regional lymph node swelling in typical presentations.

Source: CDC Public Health Image Library, public domain.

Scaffold before and after Bartonella henselae growth showing aggregates and biofilm

B. henselae biofilm scaffold

Scaffold microscopy showing Bartonella henselae aggregate growth and biofilm formation. The progression from clean scaffold to aggregates to biofilm helps explain why persister-focused and biofilm-aware treatment discussions are different from simple acute-infection treatment.

Source: user-provided educational biofilm scaffold image for LADA preview.

Warthin-Starry stain showing Bartonella henselae bacilli in cardiac valve tissue

Bartonella henselae bacilli in tissue

Warthin-Starry tissue stain from a blood-culture-negative endocarditis case. The dark granules represent Bartonella henselae bacilli in cardiac valve tissue, a microscopic example of Bartonella in a clinical sample.

Source: Wikimedia Commons / CDC Emerging Infectious Diseases, public domain.

Bartonella dermatological manifestations

Educational slide summarizing dermatologic patterns reported with Bartonella, including bacillary angiomatosis, cutaneous vasculitis, annular granuloma, and sclerosing panniculitis.

Source: user-provided educational slide citing Lins KA, Drummond MR, Velho PENF, Anais Brasileiros de Dermatologia, 2019.

Chart of human disease manifestations associated with Bartonella species

Bartonella species clinical-manifestation chart

This chart maps human disease patterns to associated Bartonella species, including cat scratch disease, Carrión's disease, trench fever, bacillary angiomatosis, bacteremia, culture-negative endocarditis, and ocular or neurologic presentations.

Source: Richard I. Horowitz, MD / Medical Detective educational material. CDC Bartonella guidance and peer-reviewed species literature are listed below for context.

Research and clinical sources

Bartonella care needs a clinician who understands intracellular infection, neuropsychiatric safety, and monitored combination therapy.

These sources are not instructions to self-prescribe antibiotics, dapsone, methylene blue, or herbal antimicrobials.

Urgent or same-day evaluation

Seek urgent care for suicidal thoughts, psychosis, seizure, fainting, chest pain, stroke-like symptoms, severe eye pain, sudden vision change, high fever, or rapidly worsening neurologic symptoms.

Tell the clinician about tick, cat, flea, or lice exposure.
Bring all psychiatric medications and supplements for interaction review.

Sources used on this page

Horowitz, R.I. (2016–2017). Initial clinical observations of dapsone's effect on Bartonella in chronic Lyme patients. How Can I Get Better? Described dapsone as a broad-spectrum persister drug with activity against Borrelia, Bartonella, and Babesia in the context of the MSIDS 16-point model.
Horowitz, R.I. and Freeman, P. (2019–2022). Clinical refinement of DDDCT protocol for Lyme-MSIDS patients with prominent Bartonella co-infection. Rifabutin increasingly preferred over rifampin for the anti-Bartonella component due to better tolerability and fewer drug interactions.
Horowitz, Fallon, and Freeman (2023). “Comparison of the Efficacy of Longer versus Shorter Pulsed High Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post Treatment Lyme Disease Syndrome with Bartonellosis and Associated Coinfections.” Microorganisms, 11(9), 2301. 25 patients with bartonellosis. 100% improved. 6–7 day pulses superior to 4-day pulses. 30.5% remission at 3–9 months post 8-week DDDCT + 5–7 day HDDCT.
Horowitz, R.I. (2025, February 19). “Bartonella: The Second Great Imitator.” Medical Detective Substack. Comprehensive review of Bartonella clinical presentations, species diversity, diagnostic challenges, and treatment principles. Establishes Bartonella as a primary driver of persistent illness in Lyme-MSIDS patients.
Horowitz, R.I. (2025, February 26). “Effective Treatments for Bartonella Infections.” Medical Detective Substack. Detailed treatment options including antibiotic tables, dosing, and sequencing. Describes the transition from standard intracellular combinations to DDDCT and HDDCT for resistant Bartonella.
Horowitz, R.I. (2025, February 26). “Treating Bartonella: Double Dose Dapsone Combination Therapy.” Medical Detective Substack. Bartonella-specific DDDCT protocol with companion drug dosing tables, supportive supplements, and safety monitoring parameters.
Horowitz, R.I. (2025, March 5). “Treating Bartonella: Two-Week Pulsing.” Medical Detective Substack. Post-DDDCT/HDDCT maintenance pulsing strategy for patients with residual Bartonella symptoms. Two-week on / two-week off cycling approach.
Medical Detective Substack. Ongoing clinical education on Bartonella, MSIDS, dapsone protocols, and Babesia from Dr. Richard Horowitz.
CDC: About Bartonella — Bartonella transmission routes, main human-associated species, and tick-transmission caution.
CDC: Clinical Overview of Cat Scratch Disease — B. henselae clinical presentation, diagnosis, and disseminated disease notes.
CDC: Clinical Overview of Bartonella quintana — relapsing fever, shin/bone pain, prolonged bacteremia, endocarditis, and bacillary angiomatosis.
CDC: Clinical Guidance for Bartonella bacilliformis — Oroya fever, Verruga peruana, endocarditis, diagnosis, and treatment guidance.
Mozayeni, R., MD, and Breitschwerdt, E.B., DVM. Clinical research and published frameworks for the diagnosis and treatment of persistent Bartonella infection. Galaxy Diagnostics and Bartonella Institute.
Breitschwerdt, E.B. et al. (2009–2025). Bartonella pathogenesis, BAPGM enrichment culture methodology, documentation of persistent Bartonella bacteremia in humans with chronic illness.
Stephen Harrod Buhner, Healing Lyme Disease Coinfections
McFadzean and Burrascano, The Beginner's Guide to Lyme Disease
William Rawls, MD, Unlocking Lyme — Chapter on stealth microbes including Bartonella

Safety first

Bartonella treatment is not a do-it-yourself protocol.

Combination antimicrobial therapy can involve serious drug interactions, liver effects, blood-count changes, psychiatric effects, pregnancy concerns, dapsone-related anemia or methemoglobinemia, and medication intolerance. LADA's role is advocacy and navigation.

Find LLMD Support Take Questionnaire